Oxidant-antioxidant status in relation to survival among breast cancer patients.
The role of plasma oxidant-antioxidant status in survival after breast cancer surgery was investigated in a cohort of patients (n = 363) hospitalized in Southern France between 1989 and 1992. The median follow-up was 8 years after surgery for histologically confirmed breast cancer. Plasma analyses were performed after diagnosis and before surgery and adjuvant therapy. We found an inverse relationship between plasma lipoperoxides (MDA) and tumor size at diagnosis, together with higher lipoperoxide levels in node-negative tumors than in node-positive ones (TNM). The longitudinal approach revealed an increased risk of recurrence for patients with plasma lipoperoxides in the highest tertile of the sample (RR = 2.1, 95% CI 1.1-4.0). In addition, the risk of recurrence increased (RR = 1.7, 95%CI 1.0-3.0), after adjustment for the known prognostic factors (TNM), for patients with plasma lipid-adjusted vitamin E levels of over 22 micromol/l. The risk of breast cancer death was twice as great for patients with plasma lipid-adjusted vitamin E levels above this value. Excesses of plasma lipoperoxides and vitamin E appear to be factors in poor prognosis for breast cancer-specific survival (OVS) and disease-free survival (DFS), respectively, independent of tumor characteristics at diagnosis. Several hypotheses are advanced to explain the possible role of plasma vitamin E as a factor in poor prognosis for survival.
Saintot
Monique
M
Centre de Recherche en Cancerologie, INSERM-CRLCC, Val D'Aurelle, Parc Euromedecine, Montpellier, France.
Mathieu-Daude
Hélène
H
Astre
Cécile
C
Grenier
Jean
J
Simony-Lafontaine
Joelle
J
Gerber
Mariette
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000556:secondary / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000453:epidemiology / Q000378:metabolism* / Q000601:surgery; D018275:Carcinoma, Lobular / Q000453:epidemiology / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D008137:Longitudinal Studies; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016877:Oxidants / Q000097:blood*; D011960:Receptors, Estrogen / Q000378:metabolism; D015996:Survival Rate
D000975:Antioxidants; D015415:Biomarkers; D008054:Lipid Peroxides; D016877:Oxidants; D011960:Receptors, Estrogen; D002784:Cholesterol